FutureBridge Releases Tumor Report on the Future of NSCLC Treatment and Evolving Trends [Video]

MUMBAI, India, May 2, 2024 /PRNewswire/ — FutureBridge, a leading techno-commercial consulting and advisory company, tracks the future of therapies and related trends from a 1-to-25-year perspective and introduces its insightful report, “Future of NSCLC Treatment & Evolving Trends”. This report is based on its proprietary methodology and combination of human and artificial intelligence, exploring transformative signals shaping the Oncology market.

To offer comprehensive analysis and detailed perspectives on the Non-Small Cell Lung Cancer (NSCLC) treatment landscape, FutureBridge analysts monitored approximately 2400 clinical trials, tracked over 700 assets from around 350 industry entities, and examined more than 600 scientific papers.

Key insights are focused on:

• Competitive landscape, dynamics, unmet needs, treatment trends, regulatory approvals, and asset progression
• Potential therapeutic opportunities such as immunotherapy-ineligible frontline NSCLC patients
• Promising approaches for emerging populations of PD-1/L1 progressors or Osimertinib progressors
• Emerging patient populations, biomarkers, novel endpoints, etc. differentiating the target patient …